Skip to Content
NewsPress Releases

22nd Century Group (Nasdaq: XXII) Acquires GVB Biopharma

May 16, 2022

Shulman Rogers Mergers & Acquisitions team was pleased to provide support to 22nd Century Group (Nasdaq: XXII) in its recently announced acquisition of GVB Biopharma.

22nd Century Group is a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technology. Acquiring GVB Biopharma, one of the largest providers of hemp-derived active ingredients for the pharmaceutical and consumer goods industries worldwide, will enable 22nd Century Group to rapidly grow its hemp/cannabis franchise and complement its existing upstream and downstream value chains.

The Shulman Rogers deal team, was led by Scott Museles and included Aaron Ghais, Eric Kurtz, Paul Schwinn and Justin Meltzer. 

“We look forward to opportunities to contribute to 22nd Century Group’s continued success,” said Museles. “And, we were thrilled to support the 22nd Century Group leadership team on completing this transformational deal in the cannabis/hemp space in a challenging market environment.”

Click HERE to read the full press release.